User login
The U.S. Senate is the next stop for the 21st Century Cures Act, approved by the House of Representatives on July 10th. Peter L. Saltonstall, President and CEO of NORD, issued a statement at the time of the House approval calling the action “a huge win for the rare disease community” and praising, in particular, the legislation’s:• Mandatory funding for NIH
• Strengthening FDA’s ability to streamline the clinical trials process and
• Further incentivizing the development of orphan products
NORD’s Washington DC-based policy team now is meeting with Senate HELP (Health, Education, Labor and Pensions) Committee members to discuss provisions within 21st Century Cures that are particularly important to the rare disease community. The legislation was introduced to promote innovation in medical research, the development of therapies, and the delivery of health services.
The U.S. Senate is the next stop for the 21st Century Cures Act, approved by the House of Representatives on July 10th. Peter L. Saltonstall, President and CEO of NORD, issued a statement at the time of the House approval calling the action “a huge win for the rare disease community” and praising, in particular, the legislation’s:• Mandatory funding for NIH
• Strengthening FDA’s ability to streamline the clinical trials process and
• Further incentivizing the development of orphan products
NORD’s Washington DC-based policy team now is meeting with Senate HELP (Health, Education, Labor and Pensions) Committee members to discuss provisions within 21st Century Cures that are particularly important to the rare disease community. The legislation was introduced to promote innovation in medical research, the development of therapies, and the delivery of health services.
The U.S. Senate is the next stop for the 21st Century Cures Act, approved by the House of Representatives on July 10th. Peter L. Saltonstall, President and CEO of NORD, issued a statement at the time of the House approval calling the action “a huge win for the rare disease community” and praising, in particular, the legislation’s:• Mandatory funding for NIH
• Strengthening FDA’s ability to streamline the clinical trials process and
• Further incentivizing the development of orphan products
NORD’s Washington DC-based policy team now is meeting with Senate HELP (Health, Education, Labor and Pensions) Committee members to discuss provisions within 21st Century Cures that are particularly important to the rare disease community. The legislation was introduced to promote innovation in medical research, the development of therapies, and the delivery of health services.
